Oric Pharmaceuticals (ORIC) Jefferies 2024 Global Healthcare Conference summary

Pipeline and program overview

• Focus on small molecule drug development for solid tumors, especially lung, prostate, and breast cancers.

• Three programs completed phase 1 studies; two advancing to later-stage development: ORIC-944 (PRC2 inhibitor for prostate cancer) and ORIC-114 (brain-penetrant TKI for EGFR/HER2 exon 20 mutations).

• ORIC-944 and ORIC-114 are prioritized for further development based on recent data.

ORIC-944: PRC2 EED inhibitor for prostate cancer

• Demonstrates superior drug properties over competitors, including a 20-hour half-life and no CYP autoinduction.

• Preclinical and translational data show equal or better efficacy compared to Pfizer’s 1497, with strong synergy with AR modulators.

• Combination studies with AR inhibitors initiated in 1H 2024; program update expected mid-year.

• No preference among AR inhibitors for combination; protocol allows flexibility for future phase 3 studies.

• Large addressable market in metastatic CRPC; phase 3 strategies may mirror Pfizer’s approach.

ORIC-114: Brain-penetrant TKI for EGFR/HER2 exon 20 mutations

• Differentiates from competitors by demonstrating CNS activity and minimized off-target toxicities.

• ESMO 2023 data showed RECIST and CNS responses in heavily pretreated patients, including those with untreated brain metastases.

• Expansion cohorts include EGFR exon 20 inhibitor-naive, HER2 exon 20, and EGFR atypical mutations; strong investigator interest in frontline naive cohort.

• Phase 1b data updates expected 1H 2025; pivotal studies may start in 2H 2025, with NDA filings targeted for 2H 2027.

• Success bar includes 35-40% ORR and demonstration of CNS activity; wide therapeutic index supports dose selection.